Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

Evidence suggests that Journavx doesn't pose a risk of addiction as opioid medications do, making it a potentially safer alternative for pain management. "A new therapeutic class of non-opioid ...

Arbuckle claims, as industry executives often do, that his team has had fruitful conversations with these stakeholders, that they appreciate Journavx may fill a major gap in pain management.

"This action and the agency’s designations to expedite the drug’s development and review underscore FDA’s commitment to approving safe and effective alternatives to opioids for pain management.” ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

“With the approval of Journavx, a non-opioid ... we have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Vertex’s chief executive ...

Journavx was evaluated in two random double ... "We have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Kewalramani said.